Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction

Journal of the American College of Cardiology

Volumn 35, Issue 6, 2000, Pages 1516-1524

  French, John K ^a   Hyde, Thomas A ^a   Straznicky, Ivan T ^a   Andrews, Jacqueline ^a   Lund, Mayanna ^a   Amos, David J ^a   Zambanini, Andrew ^a   Ellis, Christopher J ^a   Webber, Bruce J ^a   McLaughlin, Stephanie C ^a   Whitlock, Ralph M L ^a   Manda, Samuel O M ^a   Patel, Hitesh ^a   White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTITHROMBOCYTIC AGENT; HEPARIN; PLACEBO; STREPTOKINASE;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; EXERCISE; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; SURVIVAL;

ADULT; AGED; BLOOD FLOW VELOCITY; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; STREPTOKINASE; SURVIVAL RATE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0034124609     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00577-5     Document Type: Article

References (27)

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1:1986;397-402.
2. Simes R.J., Topol E.J., Holmes D.R. Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion importance of early and complete infarct artery reperfusion . Circulation. 91:1995;1923-1928.
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction ISIS-2 . Lancet. 2:1988;349-360.
4. White H.D., Norris R.M., Brown M.A., et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 317:1987;850-855.
5. French J.K., Hyde T.A., White H.D. Left ventricular function following thrombolytic therapy for myocardial infarction. J Interven Cardiol. 11:1998;9-18.
6. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge . Circulation. 76:1987;142-154.
7. White C.W. Simplicity's virtue scorned precision comes to TIMI flow grading and the results are ... surprising . [editorial] Circulation. 93:1996;853-856.
8. Bode C., Smalling R.W., Berg G., et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 94:1996;891-898.
9. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count a quantitative method of assessing coronary artery flow . Circulation. 93:1996;879-888.
10. Dodge J.T. Jr, Gibson C.M., Nykiel M., et al. Impact of injection rate on the Thrombolysis in Myocardial Infarction (TIMI) trial frame count. Am J Cardiol. 81:1998;1268-1270.
11. French J.K., Straznicky I.T., Webber B.J., et al. Angiographic frame counts 90 minutes after streptokinase predict left ventricular function at 48 hours following myocardial infarction. Heart. 81:1999;128-133.
12. French J.K., Ellis C.J., Webber B.J., et al. Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. Am J Cardiol. 81:1998;665-671.
13. White H.D., Rivers J.T., Maslowski A.H., et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med. 320:1989;817-821.
14. French J.K., Amos D.J., Williams B.F., et al. Effects of early captopril administration after thrombolysis on regional wall motion in relation to infarct artery blood flow. J Am Coll Cardiol. 33:1999;139-145.
15. French J.K., Williams B.F., Hart H.H., et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ. 312:1996;1637-1641.
16. Braunwald E., Kloner R.A. The stunned myocardium prolonged, postischemic ventricular dysfunction . Circulation. 66:1982;1146-1149.
17. White H.D., Aylward P.E., Frey M.J., et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 96:1997;2155-2161.
18. Gibson C.M., Murphy S.A., Rizzo M.J., et al. The relationship between the TIMI frame count and clinical outcomes following thrombolytic administration. Circulation. 99:1999;1945-1950.
19. The National Heart, Lung, and Blood Institute Coronary Artery Surgery Study (CASS) a multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease, and a registry of consecutive patients undergoing coronary angiography . Circulation. 63:1981;I-1-I-81.
20. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
21. Liem A., Zijlstra F., Ottervanger J.P., et al. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction the Heparin in Early Patency (HEAP) Randomised Trial . J Am Coll Cardiol. 35:2000;600-604.
22. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. [published erratum appears in N Engl J Med 1994;330:516] N Engl J Med. 329:1993;1615-1622.
23. Reiner J.S., Lundergan C.F., Fung A., et al. Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. Circulation. 94:1996;2441-2446.
24. French J.K., Hyde T.A., Patel H., et al. Survival 12 years after randomization to streptokinase the influence of Thrombolysis in Myocardial Infarction flow at three to four weeks . J Am Coll Cardiol. 34:1999;62-69.
25. Ross A.M., Coyne K.S., Moreyra E., et al. Extended mortality benefit of early postinfarction reperfusion. Circulation. 97:1998;1549-1556.
26. Lenderink T., Simoons M.L., van Es G.-A., et al. Benefit of thrombolytic therapy is sustained throughout 5 years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation. 92:1995;1110-1116.
27. Villella A., Maggioni A.P., Villella M., et al. Prognostic significance of maximal exercise testing after myocardial infarction treated with thrombolytic agents the GISSI-2 data-base: Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto . Lancet. 346:1995;523-529.